FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Flores Osvaldo	2. Date of Requiring (Month/Da 06/17/20	Statement ay/Year)	3. Issuer Name and Ticker or Trading Symbol Century Therapeutics, Inc. [IPSC]				
(Last) (First) (Middle) 3675 MARKET STREET	00/1//20	J21	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give Other (specify title below) below) Chief Executive Officer		wner specify	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person	
(Street) PHILADELPHIA PA 19103	_						
(City) (State) (Zip)	Fahle I - No	n-Derivat	 ive Securities Benefi	cially Ov	vned		
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Owner Form: D (D) or Ir (I) (Instr	ership 4 Direct C	4. Nature of Indirect Beneficial Ownership (Instr. 5)	
Common Stock			526,839	Г)		
Common Stock			397,440	I		By NS Irrevocable Trust for Gabriel O. Flores	
Common Stock			397,440	I		By Flores Family Trust for Gabriel O. Flores	
(e.			e Securities Beneficiants, options, convert				
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Se Underlying Derivative Sec (Instr. 4)		4. Convers or Exerc		6. Nature of Indirect Beneficial Ownership (Instr.
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	e or Indirect	5)
Stock Option (right to buy)	(1)	10/01/2030	Common Stock	213,624	1.74	D	
Stock Option (right to buy)	(2)	04/15/2031	Common Stock	777,417	7.27	D	

Explanation of Responses:

- 1. The option vests on the earlier of (a) the Issuer's closing of a business development transaction prior to June 30, 2021 or (b) the Issuer's closing of an initial public offering prior to August 13, 2021, in each case subject to the Reporting Person's continued service with the Issuer.
- 2. The option vests 25% on the first anniversary of the closing of the Issuer's initial public offering, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.

By: /s/ Michael Diem, Attorney-in-Fact

06/17/2021

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints the Chief Business Officer of Century Therapeutics, Inc. (the "Company"), as the undersigned's true and lawful attorney-in-fact to:

- 1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4 and 5, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to (A) complete and execute any such Forms 3, 4 or 5 (B), complete and execute any amendment or amendments thereto, and (C) timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- 3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of May, 2021.

/s/ Osvaldo Flores, Ph.D. Osvaldo Flores, Ph.D.